Welcome to our dedicated page for Molina Hlthcare SEC filings (Ticker: MOH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Molina Healthcare, Inc. filings document the regulatory record for a managed healthcare company serving Medicaid, Medicare and state insurance marketplace programs. Its 8-K reports disclose operating results, premium revenue and earnings guidance, Regulation FD investor presentations, material agreements, direct financial obligations, impairment charges and senior unsecured note financing.
The company's proxy and governance filings cover annual meeting proposals, director and executive compensation matters, equity incentive plan authorization and amendments to charter or bylaw provisions such as stockholder special-meeting rights. The filing record also describes capital-structure terms, credit agreement covenants, risk-factor references and shareholder voting outcomes.
Molina Healthcare director receives routine equity compensation in stock. A company director was granted 317 shares of Molina Healthcare common stock on January 1, 2026 under the 2025 Equity Incentive Plan, for services as a director. The grant represents one quarterly installment of an annual equity award with an aggregate value of $220,000, with this quarter’s portion set at $55,000. Because January 1, 2026 was a non-trading day, the shares were calculated using the December 31, 2025 closing price of $173.54 per share. Following this grant, the director beneficially owns 900 shares directly.
Molina Healthcare director reports routine stock grant
A director of Molina Healthcare, Inc. reported receiving 317 shares of common stock on January 1, 2026 under the company’s 2025 Equity Incentive Plan for board service. The quarterly grant represents one quarter of an annual equity award valued at $220,000, with this quarter’s $55,000 portion calculated using the $173.54 closing price of Molina Healthcare common stock on December 31, 2025, because January 1 was a non-trading day.
After this award, the reporting person beneficially owns 14,991 shares of Molina Healthcare common stock, held indirectly through the Dale B. Wolf Revocable Trust, for which he serves as sole trustee. The filing describes this as compensation for services as a director rather than an open-market purchase or sale.
Molina Healthcare, Inc. reported a routine equity grant to one of its directors. On January 1, 2026, the director received 317 shares of Molina common stock under the company’s 2025 Equity Incentive Plan as compensation for board service. The grant represents one quarterly portion of an annual equity award valued at $220,000, with this quarter’s installment set at $55,000.
The number of shares was calculated using the closing price of Molina’s common stock of $173.54 on December 31, 2025, because the grant date was a non‑trading day. Following this grant, the director beneficially owns 5,176 shares of Molina Healthcare common stock, held directly.
Molina Healthcare executive Debra Bacon, EVP of Medicaid, reported acquiring company stock through an employee plan. On December 31, 2025, she purchased 22 shares of common stock under the Molina Healthcare, Inc. 2019 Employee Stock Purchase Plan. The purchase price was $147.51 per share, equal to 85% of $173.54, which was the closing price on the last trading day of the ESPP offering period. After this transaction, she beneficially owns 12,906 shares directly. The filing also notes a vesting schedule for previously granted shares, with tranches vesting on March 1, 2026, July 1, 2026, March 1, 2027, and March 1, 2028.
Molina Healthcare, Inc. (MOH) reported an insider stock transaction by one of its directors. On 11/24/2025, the director sold 357 shares of Molina common stock in an open-market transaction coded as a sale.
The shares were sold at a volume-weighted average price of $143.02, with individual trade prices ranging from $143.00 to $143.18. Following this transaction, the director beneficially owns 11,352 shares of Molina Healthcare common stock, held in direct ownership form.
MOH filed a Form 144 notice covering a planned sale of restricted or control securities. An affiliated holder plans to sell 357 common shares of MOH through Piper Sandler & Co. on the NYSE, with an indicated aggregate market value of $50,536.00. The filing notes that 51,400,000 common shares were outstanding.
The shares to be sold come from equity grant awards, with 189 shares acquired on 01/01/2025 and 168 shares acquired on 04/01/2025, both from the company. By signing, the seller represents they are not aware of any undisclosed material adverse information about MOH’s current or prospective operations and references the possibility of a Rule 10b5-1 trading plan.
Molina Healthcare, Inc. has completed a private offering of $850.0 million aggregate principal amount of 6.500% Senior Notes due 2031. These senior unsecured notes pay interest semi-annually on February 15 and August 15, starting August 15, 2026, and mature on February 15, 2031. The notes rank equally with Molina’s other senior unsecured debt, are subordinated to secured debt with respect to collateral, and are structurally subordinated to liabilities of its subsidiaries.
The notes are redeemable on and after December 15, 2027 at specified prices, and may be redeemed earlier with a make-whole premium. Holders receive a repurchase right upon a defined change of control. The notes were issued in a private offering without registration rights. Molina also entered into a new revolving credit agreement with Truist Bank and lenders, replacing its prior credit agreement with substantially similar terms but certain covenants amended in a manner favorable to the company.
Molina Healthcare, Inc. has priced $850 million of 6.500% senior notes due 2031 in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S. These notes are senior unsecured debt obligations of the company and are being sold in a transaction exempt from registration under the Securities Act, meaning they cannot be freely offered or sold in the United States without registration or an applicable exemption. The offering is expected to close on or about November 20, 2025, subject to customary closing conditions, and the company has issued a press release describing the pricing terms.
Molina Healthcare, Inc. has priced $850 million of 6.500% senior notes due 2031 in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S. These notes are senior unsecured debt obligations of the company and are being sold in a transaction exempt from registration under the Securities Act, meaning they cannot be freely offered or sold in the United States without registration or an applicable exemption. The offering is expected to close on or about November 20, 2025, subject to customary closing conditions, and the company has issued a press release describing the pricing terms.
Molina Healthcare, Inc. (MOH) reported that it intends to privately offer $750 million of senior notes due 2031, with net proceeds expected to repay outstanding delayed draw term loans under its existing credit facility. After repayment, the company plans to terminate that facility and enter into a fully committed new revolving credit facility that will be undrawn at closing and available for general corporate purposes. Molina noted it currently has no borrowings under the existing facility and has sufficient cash on its balance sheet. To support potential note investors, Molina shared non-GAAP performance data, including EBITDA rising from $1,349 million in 2022 to $1,893 million in 2024 and Adjusted EBITDA increasing from $1,709 million in 2022 to $2,091 million in 2024, with intermediate periods also provided.
Molina Healthcare, Inc. (MOH) reported that it intends to privately offer $750 million of senior notes due 2031, with net proceeds expected to repay outstanding delayed draw term loans under its existing credit facility. After repayment, the company plans to terminate that facility and enter into a fully committed new revolving credit facility that will be undrawn at closing and available for general corporate purposes. Molina noted it currently has no borrowings under the existing facility and has sufficient cash on its balance sheet. To support potential note investors, Molina shared non-GAAP performance data, including EBITDA rising from $1,349 million in 2022 to $1,893 million in 2024 and Adjusted EBITDA increasing from $1,709 million in 2022 to $2,091 million in 2024, with intermediate periods also provided.
Molina Healthcare (MOH) reported that Florida’s Agency for Health Care Administration issued a Notice of Agency Decision stating its intent to award Molina Healthcare of Florida a contract to provide Statewide Medicaid Managed Care (SMMC) and Children’s Health Insurance Program (CHIP) services to enrollees of the Title XIX and Title XXI Children’s Medical Services (CMS) Program. The company furnished a press release as Exhibit 99.1.